🟢 Tscan Therapeutics is trading 5% up today with broader-market gains a possible contributor

Tscan Therapeutics is trading at $0.33, up +5.45%, with broader-market strength a possible contributor, though the connection is unconfirmed.

• No new company-specific catalyst explaining the September 30 move was identified in the search.
• Tscan’s latest major update was its September 2 strategic reorganization, including a 75% workforce reduction and a pivot toward solid-tumor programs. This is prior context, not a confirmed catalyst for the gain.